BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jellinger KA. Animal models of synucleinopathies and how they could impact future drug discovery and delivery efforts. Expert Opinion on Drug Discovery 2019;14:969-82. [DOI: 10.1080/17460441.2019.1638908] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Campese N, Fanciulli A, Stefanova N, Haybaeck J, Kiechl S, Wenning GK. Neuropathology of multiple system atrophy: Kurt Jellinger`s legacy. J Neural Transm (Vienna) 2021. [PMID: 34319460 DOI: 10.1007/s00702-021-02383-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Marques CR, Pereira-Sousa J, Teixeira FG, Sousa RA, Teixeira-Castro A, Salgado AJ. Mesenchymal stem cell secretome protects against alpha-synuclein-induced neurodegeneration in a Caenorhabditis elegans model of Parkinson's disease. Cytotherapy 2021:S1465-3249(21)00228-0. [PMID: 34059421 DOI: 10.1016/j.jcyt.2021.04.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
3 Cerri S, Blandini F. In vivo modeling of prodromal stage of Parkinson’s disease. Journal of Neuroscience Methods 2020;342:108801. [DOI: 10.1016/j.jneumeth.2020.108801] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]